Key highlights
- KYORIN and UBE signed an exclusive worldwide license granting KYORIN rights to develop, manufacture and commercialize UBE's novel drug candidates.
- UBE will receive an upfront payment plus development and commercial milestone payments and royalties tied to net sales.
- KYORIN focuses development on pain, autoimmune disorders and neuromuscular disease while UBE supplies lead compounds from its organic synthesis-driven discovery.
License deal
KYORIN and UBE entered an exclusive worldwide license granting KYORIN rights to develop, manufacture and commercialize novel drug candidates discovered by UBE.
Commercial and financial terms
KYORIN will make an upfront payment to UBE; UBE is eligible for development and approval milestone payments, commercial milestones tied to specific net sales targets, and royalties on net sales.
R&D roles and strategic focus
KYORIN will apply its R&D capabilities focused on pain, autoimmune disorders and neuromuscular disease while UBE provides lead compounds from its organic synthesis-driven discovery, aiming to accelerate delivery of new treatment options for patients inadequately served by existing therapies.
